Literature DB >> 21809359

MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint.

Alexandru V Olaru1, Gabriel Ghiaur, Sumitaka Yamanaka, Delgermaa Luvsanjav, Fangmei An, Irinel Popescu, Sorin Alexandrescu, Sarah Allen, Timothy M Pawlik, Michael Torbenson, Christos Georgiades, Lewis R Roberts, Gregory J Gores, Anne Ferguson-Smith, Maria I Almeida, George A Calin, Esteban Mezey, Florin M Selaru.   

Abstract

UNLABELLED: MicroRNAs (miRs) recently emerged as prominent regulators of cancer processes. In the current study we aimed at elucidating regulatory pathways and mechanisms through which miR-494, one of the miR species found to be down-regulated in cholangiocarcinoma (CCA), participates in cancer homeostasis. miR-494 was identified as down-regulated in CCA based on miR arrays. Its expression was verified with quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR). To enforce miR expression, we employed both transfection methods, as well as a retroviral construct to stably overexpress miR-494. Up-regulation of miR-494 in cancer cells decreased growth, consistent with a functional role. mRNA arrays of cells treated with miR-494, followed by pathway analysis, suggested that miR-494 impacts cell cycle regulation. Cell cycle analyses demonstrated that miR-494 induces a significant G1/S checkpoint reinforcement. Further analyses demonstrated that miR-494 down-regulates multiple molecules involved in this transition checkpoint. Luciferase reporter assays demonstrated a direct interaction between miR-494 and the 3'-untranslated region of cyclin-dependent kinase 6 (CDK6). Last, xenograft experiments demonstrated that miR-494 induces a significant cancer growth retardation in vivo.
CONCLUSION: Our findings demonstrate that miR-494 is down-regulated in CCA and that its up-regulation induces cancer cell growth retardation through multiple targets involved in the G1-S transition. These findings support the paradigm that miRs are salient cellular signaling pathway modulators, and thus represent attractive therapeutic targets. miR-494 emerges as an important regulator of CCA growth and its further study may lead to the development of novel therapeutics.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21809359      PMCID: PMC3212606          DOI: 10.1002/hep.24591

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  43 in total

1.  Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Authors:  Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

Review 2.  Plasmid uptake by bacteria: a comparison of methods and efficiencies.

Authors:  Naoto Yoshida; Misa Sato
Journal:  Appl Microbiol Biotechnol       Date:  2009-05-27       Impact factor: 4.813

Review 3.  Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell.

Authors:  Georgia Sotiropoulou; Georgios Pampalakis; Evi Lianidou; Zissimos Mourelatos
Journal:  RNA       Date:  2009-06-26       Impact factor: 4.942

4.  MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes.

Authors:  Chiara Braconi; Nianyuan Huang; Tushar Patel
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

5.  MicroRNA-98 and let-7 confer cholangiocyte expression of cytokine-inducible Src homology 2-containing protein in response to microbial challenge.

Authors:  Guoku Hu; Rui Zhou; Jun Liu; Ai-Yu Gong; Alex N Eischeid; Jared W Dittman; Xian-Ming Chen
Journal:  J Immunol       Date:  2009-07-10       Impact factor: 5.422

Review 6.  MicroRNA control of signal transduction.

Authors:  Masafumi Inui; Graziano Martello; Stefano Piccolo
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03-10       Impact factor: 94.444

7.  NFkappaB p50-CCAAT/enhancer-binding protein beta (C/EBPbeta)-mediated transcriptional repression of microRNA let-7i following microbial infection.

Authors:  Steven P O'Hara; Patrick L Splinter; Gabriella B Gajdos; Christy E Trussoni; Martin E Fernandez-Zapico; Xian-Ming Chen; Nicholas F LaRusso
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

8.  Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.

Authors:  Robert E Lanford; Elisabeth S Hildebrandt-Eriksen; Andreas Petri; Robert Persson; Morten Lindow; Martin E Munk; Sakari Kauppinen; Henrik Ørum
Journal:  Science       Date:  2009-12-03       Impact factor: 47.728

Review 9.  Causes and consequences of microRNA dysregulation in cancer.

Authors:  Carlo M Croce
Journal:  Nat Rev Genet       Date:  2009-10       Impact factor: 53.242

10.  MiR-320 and miR-494 affect cell cycles of primary murine bronchial epithelial cells exposed to benzo[a]pyrene.

Authors:  Huihan Duan; Yiguo Jiang; Hongyu Zhang; Yan Wu
Journal:  Toxicol In Vitro       Date:  2009-11-16       Impact factor: 3.500

View more
  53 in total

Review 1.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

Review 2.  Animal models of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Samantha R Fischbach; Gregory J Gores; Sumera Rizvi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-05       Impact factor: 5.187

Review 3.  MicroRNAs and benign biliary tract diseases.

Authors:  Sergio A Gradilone; Steven P O'Hara; Tetyana V Masyuk; Maria Jose Lorenzo Pisarello; Nicholas F LaRusso
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

Review 4.  MicroRNAs in biliary diseases.

Authors:  Patricia Munoz-Garrido; Maite García-Fernández de Barrena; Elizabeth Hijona; Miguel Carracedo; José J G Marín; Luis Bujanda; Jesús M Banales
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

Review 5.  The role of miRNAs in cholangiocarcinoma.

Authors:  Jessica A Howell; Shahid A Khan
Journal:  Hepat Oncol       Date:  2016-03-29

Review 6.  Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy.

Authors:  Domenico Viterbo; Valerie Gausman; Tamas Gonda
Journal:  World J Gastrointest Endosc       Date:  2016-02-10

7.  Mir-494 inhibits osteoblast differentiation by regulating BMP signaling in simulated microgravity.

Authors:  WeiWei Qin; Li Liu; YongChun Wang; Zhe Wang; AnGang Yang; Tao Wang
Journal:  Endocrine       Date:  2019-05-25       Impact factor: 3.633

8.  LncRNA PCAT6 increased cholangiocarcinoma cell proliferation and invasion via modulating miR-330-5p.

Authors:  Yongjie Xin; Xu He; Wei Zhao; Meixiao Zhan; Yong Li; Jing Xiao; Ke He; Ligong Lu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 9.  Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma.

Authors:  Hiroaki Haga; Irene Yan; Kenji Takahashi; Joseph Wood; Tushar Patel
Journal:  Gene Expr       Date:  2014

10.  MicroRNAs in Cholangiopathies.

Authors:  Steven P O'Hara; Sergio A Gradilone; Tetyana V Masyuk; James H Tabibian; Nicholas F LaRusso
Journal:  Curr Pathobiol Rep       Date:  2014-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.